Quarterly Accumulated Depreciation & Amortization rose 1091.78% to $63.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $63.5 million through Mar 2026, up 1091.78% year-over-year, with the annual reading at $57.6 million for FY2025, 45.06% up from the prior year.
Accumulated Depreciation & Amortization hit $63.5 million in Q1 2026 for AbCellera Biologics, up from $57.6 million in the prior quarter.
Across five years, Accumulated Depreciation & Amortization topped out at $63.5 million in Q1 2026 and bottomed at $4.8 million in Q1 2024.
Average Accumulated Depreciation & Amortization over 5 years is $24.7 million, with a median of $24.2 million recorded in 2023.
The largest annual shift saw Accumulated Depreciation & Amortization tumbled 86.78% in 2025 before it soared 1091.78% in 2026.
AbCellera Biologics' Accumulated Depreciation & Amortization stood at $27.8 million in 2022, then decreased by 12.38% to $24.4 million in 2023, then soared by 62.81% to $39.7 million in 2024, then surged by 45.06% to $57.6 million in 2025, then grew by 10.28% to $63.5 million in 2026.
Per Business Quant, the three most recent readings for ABCL's Accumulated Depreciation & Amortization are $63.5 million (Q1 2026), $57.6 million (Q4 2025), and $16.0 million (Q3 2025).

Peer Comparison

Historic Data

Download Data 🔒

Date	Value